MMP14 and neoplasm: For instance, azademethylcolchicine, a vascular disrupting agent that is utilized against solid tumors but has the untoward side effects of cardiotoxicity, has been developed into a MMP-14 activatable form termed ICT2588 (ICT) that avoids the unfavorable side effect profile by selectively activating in tumor tissues [252].